Japan’s Ongoing Crisis on HPV Vaccination
<b>: </b>The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated befo...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/3/362 |
id |
doaj-7d80e79d04d64072901d51a2dcc64da2 |
---|---|
record_format |
Article |
spelling |
doaj-7d80e79d04d64072901d51a2dcc64da22020-11-25T03:13:11ZengMDPI AGVaccines2076-393X2020-07-01836236210.3390/vaccines8030362Japan’s Ongoing Crisis on HPV VaccinationMasayuki Sekine0Risa Kudo1Manako Yamaguchi2Sharon J. B. Hanley3Megumi Hara4Sosuke Adachi5Yutaka Ueda6Etsuko Miyagi7Sayaka Ikeda8Asami Yagi9Takayuki Enomoto10Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartment of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, JapanDepartment of Preventive Medicine, Faculty of Medicine, Saga University, Saga 849-8501, JapanDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, JapanDepartments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Obstetrics and Gynecology, Yokohama City University School of Medicine, Yokohama 236-0004, JapanDivision of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka 565-0871, JapanDepartments of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, JapanDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan<b>: </b>The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government.https://www.mdpi.com/2076-393X/8/3/362HPV vaccineHPV infectioncervical canceradverse reactionJapanese governmentsuspension of proactive recommendation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Masayuki Sekine Risa Kudo Manako Yamaguchi Sharon J. B. Hanley Megumi Hara Sosuke Adachi Yutaka Ueda Etsuko Miyagi Sayaka Ikeda Asami Yagi Takayuki Enomoto |
spellingShingle |
Masayuki Sekine Risa Kudo Manako Yamaguchi Sharon J. B. Hanley Megumi Hara Sosuke Adachi Yutaka Ueda Etsuko Miyagi Sayaka Ikeda Asami Yagi Takayuki Enomoto Japan’s Ongoing Crisis on HPV Vaccination Vaccines HPV vaccine HPV infection cervical cancer adverse reaction Japanese government suspension of proactive recommendation |
author_facet |
Masayuki Sekine Risa Kudo Manako Yamaguchi Sharon J. B. Hanley Megumi Hara Sosuke Adachi Yutaka Ueda Etsuko Miyagi Sayaka Ikeda Asami Yagi Takayuki Enomoto |
author_sort |
Masayuki Sekine |
title |
Japan’s Ongoing Crisis on HPV Vaccination |
title_short |
Japan’s Ongoing Crisis on HPV Vaccination |
title_full |
Japan’s Ongoing Crisis on HPV Vaccination |
title_fullStr |
Japan’s Ongoing Crisis on HPV Vaccination |
title_full_unstemmed |
Japan’s Ongoing Crisis on HPV Vaccination |
title_sort |
japan’s ongoing crisis on hpv vaccination |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2020-07-01 |
description |
<b>: </b>The Japanese government suspended proactive recommendations for the HPV vaccine in June 2013. The suspension is now in its seventh year, despite all the data pointing to the safety of the HPV vaccine. We reported a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also lower in the vaccinated group, and the vaccine effectiveness was 67.7%. Furthermore, prevalence of HPV16, 31 and 52 infection rates in the vaccinated group were obviously lower than that in the unvaccinated group, and no one had HPV18 or 45 infection in the vaccinated group. The addition of a cross-protective effect toward HPV types 31/45/52 to HPV types 16/18, which is the direct target of the bivalent HPV vaccine, may possibly prevent around 82% of invasive cervical cancer cases in Japan. With regard to the preventive effect of histological abnormalities, we also reported significant reduction in incidence of cervical intraepithelial neoplasia (CIN)3 or worse. Thus, the efficacy of the vaccine has been demonstrated for precancerous disease, and the diverse symptoms after HPV vaccination are likely functional somatic. For the future of Japanese girls, there is a need to resume the proactive recommendation of HPV vaccination and for immediate action to be taken by the Japanese government. |
topic |
HPV vaccine HPV infection cervical cancer adverse reaction Japanese government suspension of proactive recommendation |
url |
https://www.mdpi.com/2076-393X/8/3/362 |
work_keys_str_mv |
AT masayukisekine japansongoingcrisisonhpvvaccination AT risakudo japansongoingcrisisonhpvvaccination AT manakoyamaguchi japansongoingcrisisonhpvvaccination AT sharonjbhanley japansongoingcrisisonhpvvaccination AT megumihara japansongoingcrisisonhpvvaccination AT sosukeadachi japansongoingcrisisonhpvvaccination AT yutakaueda japansongoingcrisisonhpvvaccination AT etsukomiyagi japansongoingcrisisonhpvvaccination AT sayakaikeda japansongoingcrisisonhpvvaccination AT asamiyagi japansongoingcrisisonhpvvaccination AT takayukienomoto japansongoingcrisisonhpvvaccination |
_version_ |
1724648114114002944 |